ERAS

Erasca, Inc. (ERAS) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Erasca, Inc. is a clinical-stage precision oncology company focused on discovering and developing therapies for RAS/MAPK pathway-driven cancers. The company operates as a single segment and has no approved products or product revenue. It is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Increase in Net Loss: The net loss for the six months ended June 30, 2026, increased to $227.5 million from $64.8 million in the prior year period. This was primarily driven by a $150.0 million non-cash IPR&D expense related to the exercise of an option to expand the territory of the license agreement with Guangzhou Joyo Pharmatech Co., Ltd. to include mainland China, Hong Kong, and Macau.
• Operating Expense Growth: Total operating expenses rose to $235.5 million (YTD 2026) from $73.8 million (YTD 2025). Excluding the IPR&D charge, organic operating expenses increased due to expanded clinical trial activities for ERAS-0015 and ERAS-4001, higher personnel costs, and increased stock-based compensation.
• Capital Raise: In January 2026, the company completed an underwritten offering raising net proceeds of $242.7 million. Subsequent to the reporting period (July 2026), the company completed another offering raising $593.5 million.
• Portfolio Rationalization: The company terminated its license agreement with Novartis for naporafenib, effective June 3, 2026, to prioritize resources for its RAS-targeting franchise.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes that cash, cash equivalents, and marketable securities as of June 30, 2026 ($384.3 million), combined with the net proceeds from the July 2026 offering ($593.5 million), will be sufficient to fund operations for at least the next 12 months.
• Clinical Milestones:
  • ERAS-0015 (Pan-RAS Molecular Glue): Positive preliminary Phase 1 data announced in April and July 2026 showing robust monotherapy response rates in NSCLC and PDAC. Expansion cohorts and combination trials (with panitumumab and pembrolizumab) are ongoing. Data readouts expected in H1 2027.
  • ERAS-4001 (Pan-KRAS Inhibitor): Phase 1 monotherapy data readout expected in H2 2026.
• Legal Proceedings:
  • Securities Class Action: A complaint was filed on June 10, 2026, alleging violations of federal securities laws. The company intends to defend vigorously.
  • Stockholder Derivative: A complaint was filed in August 2026 alleging breaches of fiduciary duty regarding oversight of ERAS-0015.
  • IP Dispute: In April 2026, Revolution Medicines (RevMed) sent a letter alleging that ERAS-0015 infringes their patents and misappropriates trade secrets. RevMed demanded cessation of activities. Erasca disputes these claims.
• Risks: The company has no revenue and expects to incur significant losses for the foreseeable future. Success depends on clinical trial results, regulatory approvals, and the ability to raise additional capital. Litigation outcomes are uncertain and could be costly.

Investor Verification Checklist

• Verify the status and potential financial impact of the Revolution Medicines IP dispute regarding ERAS-0015.
• Confirm the timeline and budget for the upcoming Phase 1 data readouts for ERAS-0015 and ERAS-4001.
• Monitor the progress of the securities class action and derivative lawsuits filed in mid-2026.
• Review the utilization of the $593.5 million raised in the July 2026 offering to ensure it extends the runway as projected.
• Assess the strategic implications of terminating the naporafenib program and the focus on the RAS-targeting franchise.